Pharmacokinetic considerations in seasonal malaria chemoprevention
Issued Date
2022-08-01
Resource Type
ISSN
14714922
eISSN
14715007
Scopus ID
2-s2.0-85131809192
Pubmed ID
35688778
Journal Title
Trends in Parasitology
Volume
38
Issue
8
Start Page
673
End Page
682
Rights Holder(s)
SCOPUS
Bibliographic Citation
Trends in Parasitology Vol.38 No.8 (2022) , 673-682
Suggested Citation
Chotsiri P., White N.J., Tarning J. Pharmacokinetic considerations in seasonal malaria chemoprevention. Trends in Parasitology Vol.38 No.8 (2022) , 673-682. 682. doi:10.1016/j.pt.2022.05.003 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/84946
Title
Pharmacokinetic considerations in seasonal malaria chemoprevention
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing.